Memory Disorders Research

Investigator:Paul Schulz, MD

Purpose:Eli Lilly and Company/Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease.

Key Inclusion Criteria:60-85 yrs with mild AD symptoms; ability to undergo PET scans; requires study partner.

Enrollment Status:Opening in near future

Contact Us:To learn more about this trial,please fill out this short online form »

Investigator:Paul Schulz, MD, Cameron Jeter, MD

Key Inclusion Criteria:50 -90 yrs mild cognitive impairment or early AD symptoms; requires study partner.

Enrollment Status:Opening in near future

Contact Us:To learn more about this trial,please fill out this short online form »

Investigator:Paul Schulz, MD

Purpose:Stem Cell Therapy for Early AD

Key Inclusion Criteria:50 -90 yrs mild cognitive impairment or early AD symptoms; requires study partner

Enrollment Status:Opening in the near future

Contact Us:To learn more about this trial,please fill out this short online form »

Investigator:Paul Schulz, MD

Purpose:Plasma Exchange for the treatment of Early AD

Key Inclusion Criteria:50 -90 yrs mild cognitive impairment or early AD symptoms; requires study partner

Enrollment Status:Opening in near future

Contact Us:To learn more about this trial,please fill out this short online form »

Please fill out the fields to receive information about an ongoing UTHealth Neurosciences clinical trial.

Name
First Last
Email
Name of Trial or Area of Interest
CAPTCHA
Consent
I agree

By checking this, I agree to allow UTHealth Neurosciences to send me emails about future events.
Email

This field is for validation purposes and should be left unchanged.